IL138021A0 - High affinity humanized anti-tag-72 monoclonal antibodies - Google Patents

High affinity humanized anti-tag-72 monoclonal antibodies

Info

Publication number
IL138021A0
IL138021A0 IL13802198A IL13802198A IL138021A0 IL 138021 A0 IL138021 A0 IL 138021A0 IL 13802198 A IL13802198 A IL 13802198A IL 13802198 A IL13802198 A IL 13802198A IL 138021 A0 IL138021 A0 IL 138021A0
Authority
IL
Israel
Prior art keywords
tag
monoclonal antibodies
high affinity
humanized anti
affinity humanized
Prior art date
Application number
IL13802198A
Other languages
English (en)
Original Assignee
Dow Chemical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dow Chemical Co filed Critical Dow Chemical Co
Publication of IL138021A0 publication Critical patent/IL138021A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5756—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving tumour-associated glycolinkage [TAG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL13802198A 1998-02-25 1998-02-25 High affinity humanized anti-tag-72 monoclonal antibodies IL138021A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1998/003679 WO1999043816A1 (fr) 1998-02-25 1998-02-25 Anticorps monoclonaux anti-tag-72 humanises et faisant preuve d'une grande affinite

Publications (1)

Publication Number Publication Date
IL138021A0 true IL138021A0 (en) 2001-10-31

Family

ID=22266462

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13802198A IL138021A0 (en) 1998-02-25 1998-02-25 High affinity humanized anti-tag-72 monoclonal antibodies

Country Status (9)

Country Link
EP (1) EP1056860B1 (fr)
JP (1) JP4080692B2 (fr)
AT (1) ATE288960T1 (fr)
AU (1) AU758358B2 (fr)
CA (1) CA2321932A1 (fr)
DE (1) DE69829001T2 (fr)
IL (1) IL138021A0 (fr)
NO (1) NO20004250L (fr)
WO (1) WO1999043816A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000026394A1 (fr) * 1998-10-31 2000-05-11 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Variants de l'anticorps monoclonal anti-carcinome de type humain cc49
US6818749B1 (en) 1998-10-31 2004-11-16 The United States Of America As Represented By The Department Of Health And Human Services Variants of humanized anti carcinoma monoclonal antibody cc49
AU2002327164A1 (en) 2001-01-29 2002-12-09 Idec Pharmaceuticals Corporation Engineered tetravalent antibodies and methods of use
EP1532162B1 (fr) 2002-06-28 2013-08-07 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Les cc49, anti-tag-72 humanises servant au diagnostic et au traitement de tumeurs chez l'homme
WO2005021594A2 (fr) 2003-08-29 2005-03-10 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Variants a peine immunogenes de l'anticorps humanise a greffe sdr cc49 et leur utilisation
KR100620554B1 (ko) 2004-06-05 2006-09-06 한국생명공학연구원 Tag-72에 대한 인간화 항체
DK1877102T3 (da) 2005-04-28 2014-07-21 Danisco Us Inc Tab-molekyler
DK2002003T3 (en) 2005-05-27 2016-03-21 Ospedale San Raffaele Srl Gene vector comprising miRNA

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0161525B1 (ko) * 1988-10-19 1998-12-01 리챠드 지. 워터맨 암치료를 위한 신규의 고친화성 변형된 항체군

Also Published As

Publication number Publication date
JP2002504371A (ja) 2002-02-12
EP1056860B1 (fr) 2005-02-09
DE69829001D1 (de) 2005-03-17
AU6439398A (en) 1999-09-15
AU758358B2 (en) 2003-03-20
NO20004250L (no) 2000-10-24
WO1999043816A1 (fr) 1999-09-02
JP4080692B2 (ja) 2008-04-23
ATE288960T1 (de) 2005-02-15
NO20004250D0 (no) 2000-08-24
DE69829001T2 (de) 2006-03-23
EP1056860A1 (fr) 2000-12-06
CA2321932A1 (fr) 1999-09-02

Similar Documents

Publication Publication Date Title
IL165063A0 (en) An antibody or fragment thereof that binds to human insulin-like growth factor-I receptor
SG170080A1 (en) Human monoclonal antibodies to o8e
WO2005080431A3 (fr) Anticorps monoclonaux bloquant specifiquement l'activite biologique d'un antigene tumoral
WO1998035693A3 (fr) Detection et modulation d'inhibiteurs de proteines d'apoptose (iap) et de polypeptides anti-apoptotiques apparentes (miap) permettant d'effectuer le diagnostic et le traitement de maladies proliferatives
EA200800094A1 (ru) Антитела cd19 и их использование
AU2003205077A1 (en) Imaging agents and methods of imaging naaladase of psma
EP2196474A3 (fr) Cibles thérapeutiques dans le cancer
IN2009KN02404A (fr)
HUP9901562A2 (hu) Anti-CEA monoklonális antitestek, az ezeket tartalmazó konjugátumok és ezek felhasználása antitest irányított enzimes előgyógyszer terápiában
WO2004058146A3 (fr) Nouvelles compositions et nouveaux procedes de traitement du cancer
IL139700A (en) Immunotherapeutic composition for the treatment of prostate cancer
IL148113A0 (en) Ovarian cancer cell and myeloma cell surface glycoproteins, antibodies thereto, and uses thereof
SG146644A1 (en) Kid3 and kid3 antibodies that bind thereto
WO2004060304A3 (fr) Compositions et procedes pour la cancerotherapie
WO2005055936A3 (fr) Procedes d'elimination de cellules tumorales par ciblage d'antigene interne expose sur des cellules tumorales apoptotiques
WO2003064593A3 (fr) Panneaux d'antigenes et procedes d'utilisation associes
WO2002064839A3 (fr) Gene amplifie de l'hepsine associee au cancer
NO20004250D0 (no) Humaniserte anti-TAG-72 monoklonale antistoffer med høy affinitet
NO20004251L (no) Humaniserte anti-CEA monoklonale antistoffer med høy affinitet
WO2003080808A3 (fr) Nouvelles compositions et nouveaux procedes pour le cancer
EA200601405A1 (ru) Гуманизированное антитело
WO2004003155A3 (fr) Les cc49, anti-tag-72 humanises servant au diagnostic et au traitement de tumeurs chez l'homme
EA200600995A1 (ru) Молекулы, ингибирующие ангиогенез, и их применение в лечении и диагностике рака
WO2002057786A3 (fr) Compositions et methodes destinees a l'utilisation de fragments de fibronectine dans le diagnostic du cancer
AU2001233917A1 (en) Bcmp-7 as marker for diagnosis of breast cancer